| Identification | Back Directory | [Name]
(S)-BOL-303242X) | [CAS]
887375-15-7 | [Synonyms]
(S)-ZK-245186
(S)-Mapracorat
(S)-BOL-303242X)
(Synonyms: (S)-ZK-245186
(S)-Mapracorat (Synonyms: (S)-ZK-245186
(SYNONYMS: (S)-ZK-245186; (S)-BOL-303242X)
7-Benzofuranpropanol, 5-fluoro-2,3-dihydro-γ,γ-dimethyl-α-[[(2-methyl-5-quinolinyl)amino]methyl]-α-(trifluoromethyl)-, (αS)- | [Molecular Formula]
C25H26F4N2O2 | [MDL Number]
MFCD31813749 | [MOL File]
887375-15-7.mol | [Molecular Weight]
462.49 |
| Chemical Properties | Back Directory | [Boiling point ]
602.1±55.0 °C(Predicted) | [density ]
1.316±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: ≥ 50.6 mg/mL (109.41 mM) | [form ]
Solid | [pka]
11.75±0.29(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Description]
(S)-Mapracorat is a selective and less active glucocorticoid receptor agonist.
(S)-Mapracorat concentration dependently inhibited TNFα secretion from activated canine PBMC with IC50 value of approximately 0.2 nM. Intradermal injection of compound 48/80 (50 μg in 50 μL saline) resulted in a clear wheal and flare reaction over the 60 min observation period. Topical pre-treatment with (S)-Mapracorat (0.1%) leads to significant reduction in the wheal and flare responses compared to vehicle (acetone) treated areas. | [References]
[1]. BÄumer W , et al. The selective glucocorticoid receptor agonist mapracorat displays a favourable safety-efficacy ratio for the topical treatment of inflammatory skin diseases in dogs. Vet Dermatol. 2017 Feb; 28(1):46-e11. |
|
|